Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

NCT01196390 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01196390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01196390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Completed
Start date
February 14, 2011
Completion date
August 15, 2023
Enrollment
203 (actual)
Sites
634

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma, stage ib esophageal cancer ajcc v7, stage iia esophageal cancer ajcc v7, stage iib esophageal cancer ajcc v7, stage iiia esophageal cancer ajcc v7, stage iiib esophageal cancer ajcc v7